Manikanta Murahari

Dr. Manikanta Murahari

College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vijayawada, India
orcid
Associate Professor, College of Pharmacy, KL University

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
PDPrasanth DSNBK
Prasanth DSNBK
MMManikanta Murahari
Manikanta Murahari
VCVivek Chandramohan
Vivek Chandramohan
SPSiva Prasad Panda
Siva Prasad Panda
LALakshmana Rao Atmakuri
Lakshmana Rao Atmakuri
CGChakravarthi Guntupalli
Chakravarthi Guntupalli
Cinnamon has been utilized to remedy a lot of afflictions of humans. Literary works illustrate that it possesses numerous biological activities. Our research study is intended to recognize the phyto-derived antiviral substances from Cinnamon against COVID-19 main protease enzyme and to understand the in silico molecular basis of its activity. In the present study, 48 isolates compounds from Cinnamon retrieved from the PubMed database, are subjected to docking analysis. Docking study was performed using Autodock vina and PyRx software. Afterwards, admetSAR, as well as DruLiTo servers, were used to investigate drug-likeness prophecy. Our study shows that the nine phytochemicals of Cinnamon are very likely against the main protease enzyme of COVID-19. Further MD simulations could identify Tenufolin (TEN) and Pavetannin C1 (PAV) as hit compounds. Utilizing contemporary strategies, these phyto-compounds from a natural origin might establish a reliable medication or support lead identification. Identified hit compounds can be further taken for in vitro and in vivo studies to examine their effectiveness versus COVID-19. Communicated by Ramaswamy H. Sarma

1 February 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
HGHema Sree Gns
Hema Sree Gns
SRSaraswathy Ganesan Rajalekshmi
Saraswathy Ganesan Rajalekshmi
MMManikanta Murahari
Manikanta Murahari
MKMamatha Krishnamurthy
Mamatha Krishnamurthy
Drug repurposing is an unconventional drug discovery approach to explore new therapeutic benefits of existing, shelved and the drugs in clinical trials. This approach is currently emerging to overcome the bottleneck constraints faced during traditional drug discovery in grounds of financial support, timeline and resources. In this direction, several efforts were made for the construction of stratagems based on bioinformatics and computational tools to intensify the repurposing process off-late. Further, advanced research has succeeded in widening its boundaries in identification of gene targets and subsequent molecular interactions of the drugs depending on available omics data. Currently, the advent of data repositories like Connectivity Map (CMap), Library Integrated Network based Cellular Signatures (LINCS), Genome Wide Association Studies (GWAS), Side Effect Resource (SIDER), and Directionality Map (DMAP) has bestowed great oppurtunity to the researchers in improving their drug repurposing research exponentially. On the otherhand, in silico approaches like pharmacophore modelling and docking techniques circumvent the routine tedious in vitro and in vivo techniques involved in former screening phases of the drugs and disease specific targets. This review elaborates on currently designed contemporary tools, databases and strategies with relevant case studies.

1 April 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
VSVasanti Suvarna
Vasanti Suvarna
PGParul Gujar
Parul Gujar
MMManikanta Murahari
Manikanta Murahari

1 November 2019 in European Journal of Pharmacology
Verified
Journal Article
Closed access
VSVasanti Suvarna
Vasanti Suvarna
VSVikas Singh
Vikas Singh
MMManikanta Murahari
Manikanta Murahari

1 March 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ASAtul Sherje
Atul Sherje
VKVaidehi Kulkarni
Vaidehi Kulkarni
MMManikanta Murahari
Manikanta Murahari
UNUsha Y. Nayak
Usha Y. Nayak
PBPritesh Bhat
Pritesh Bhat
BDBhushan Dravyakar
Bhushan Dravyakar

14 December 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
VSVasanti Suvarna
Vasanti Suvarna
MMManikanta Murahari
Manikanta Murahari
TKTabassum Khan
Tabassum Khan
PCPramila Chaubey
Pramila Chaubey
PSPreeti Sangave
Preeti Sangave
In today's world of modern medicine and novel therapies, cancer still remains to be one of the prime contributor to the death of people worldwide. The modern therapies improve condition of cancer patients and are effective in early stages of cancer but the advanced metastasized stage of cancer remains untreatable. Also most of the cancer therapies are expensive and are associated with adverse side effects. Thus, considering the current status of cancer treatment there is scope to search for efficient therapies which are cost-effective and are associated with lesser and milder side effects. Phytochemicals have been utilized for many decades to prevent and cure various ailments and current evidences indicate use of phytochemicals as an effective treatment for cancer. Hyperactivation of phosphoinositide 3-kinase (PI3K) signaling cascades is a common phenomenon in most types of cancers. Thus, natural substances targeting PI3K pathway can be of great therapeutic potential in the treatment of cancer patients. This chapter summarizes the updated research on plant-derived substances targeting PI3K pathway and the current status of their preclinical studies and clinical trials.